Belinostat: clinical applications in solid tumors and lymphoma
- 24 October 2011
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Investigational Drugs
- Vol. 20 (12), 1723-1732
- https://doi.org/10.1517/13543784.2011.629604
Abstract
Introduction: Histone deacetylase (HDAC) inhibitors have recently emerged as a novel and active class of anticancer agents. Belinostat is one member of the class that has been tested as a single agent and in combination with other chemotherapies and biological agents in the treatment of solid tumors and lymphoma. Areas covered: A literature search of pre-clinical and clinical studies of belinostat was performed. The data from these studies were analysed to summarise the progress of belinostat from Phase I to a current pivotal trial in peripheral T-cell lymphoma. The parallel development of appropriate biomarker analysis is also discussed. Expert opinion: Belinostat has demonstrated significant clinical activity in T-cell lymphomas. Although its activity as a single agent in solid tumors has been less compelling, the emerging results from combination trials are promising. However, the basis for the activity of belinostat, like that of other HDAC inhibitors, remains to be truly defined and the identification of predictive and prognostic biomarkers of activity should be established to further progress the development of this compound.Keywords
This publication has 64 references indexed in Scilit:
- Phase 2 trial of romidepsin in patients with peripheral T-cell lymphomaBlood, 2011
- Endothelial-derived tissue factor pathway inhibitor regulates arterial thrombosis but is not required for development or hemostasisBlood, 2010
- A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumoursBritish Journal of Cancer, 2010
- Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumoursEuropean Journal Of Cancer, 2010
- Novel histone deacetylase inhibitors in clinical trials as anti-cancer agentsJournal of Hematology & Oncology, 2010
- Phase II Study of Belinostat (PXD101), a Histone Deacetylase Inhibitor, for Second Line Therapy of Advanced Malignant Pleural MesotheliomaJournal of Thoracic Oncology, 2009
- Class I Histone Deacetylase Expression Has Independent Prognostic Impact in Human Colorectal Cancer: Specific Role of Class I Histone Deacetylases In vitro and In vivoClinical Cancer Research, 2008
- Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomyBritish Journal of Cancer, 2008
- The histone deacetylase inhibitor belinostat (PXD101) suppresses bladder cancer cell growth in vitro and in vivoJournal of Translational Medicine, 2007
- Anticancer activities of histone deacetylase inhibitorsNature Reviews Drug Discovery, 2006